Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Promethazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.94 |
| ▸ | HTR1A | P08908 | 6/20 | 0.94 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.94 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.94 |
| ▸ | DRD3 | P35462 | 6/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.94 |
| ▸ | DRD1 | P21728 | 5/20 | 0.94 |
| ▸ | LMNA | P02545 | 4/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.94 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.94 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Promethazine SCHEMBL29362589 | 1.00 | CYP2D6 (0.94) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL4700 | 0.97 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| (S)-Promethazine SCHEMBL2900853 | 0.97 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL26777 | 0.97 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL29372077 | 0.97 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL2962420 | 0.95 | LMNA (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL41904 | 0.95 | LMNA (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL5425141 | 0.95 | LMNA (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL5501515 | 0.95 | LMNA (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL29390401 | 0.95 | LMNA (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250367165-A1 | EMERGENCY EYE WASH | LEBRUN LABS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12410472-B2 | Method for evaluating the eye irritation potential of chemicals | IMMUNOSEARCH (FR) | 2025-09-09 | — | — | US | disclosed |
| US-20250262123-A1 | EMERGENCY EYE WASH | LEBRUN LABS LLC | 2025-08-21 | — | — | US | disclosed |
| CN-113109474-B | Method for detecting sedative drug metabolism residues in animal tissues | 吉林省农业科学院 | 2023-08-01 | — | — | CN | disclosed |
| US-20220364989-A1 | METHOD FOR MEASURING PHOTOTOXICITY OR PHOTOALLERGY AND REAGENT FOR USE THEREIN | FUJIFILM CORPORATION (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220334101-A1 | MODULATING EXTRACELLULAR MATRIX MOVEMENT | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-10-20 | — | — | US | disclosed |
| US-20220313656-A1 | NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA | Københavns Universitet (DK) | 2022-10-06 | — | — | US | disclosed |
| EP-3516070-B1 | METHOD FOR EVALUATING THE OCULAR IRRITABILITY POTENTIAL OF CHEMICAL PRODUCTS | IMMUNOSEARCH (FR) | 2021-12-15 | — | — | EP | disclosed |
| EP-3901620-A1 | PHOTOTOXICITY OR PHOTOALLERGY MEASUREMENT METHOD AND REAGENT FOR USE IN SAID MEASUREMENT METHOD | FUJIFILM Corporation (JP) | 2021-10-27 | — | — | EP | disclosed |
| WO-2006113914-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | HRH1 2287/4885CYP2D6 2282/4885CHRM2 3064/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | HRH1 1709/4885CYP2D6 3677/4885CHRM2 3821/4885 |
| US-20220313656-A1 | NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA | NR4A1, NR4A3, NR1H4 | HRH1 306/4885CYP2D6 201/4885CHRM2 37/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | HRH1 3316/4885CYP2D6 4288/4885CHRM2 3976/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | HRH1 1245/4885CYP2D6 3664/4885CHRM2 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.